Time filter

Source Type

Patent
SUZHOU SCISCAPE BIOMEDICINE SCIENCE & TECHNOLOGY Co. and Academy Of Military Medical Science | Date: 2015-11-13

The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohns disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patients pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.


Patent
Suzhou Sciscape Biomedicine Science & Technology Co. and Academy Of Military Medical Science | Date: 2014-05-14

The application of flagellin derivative CZLC31 from Salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (IBD) is introduced in this invention. The CZLC331 protein has a good preventive and therapeutic effect for IBD, such as ulcerative colitis (UC) and Crohns disease (CD) in this invention. Therefore, this protein can be prepared into the drug for prevention and treatment of IBD. It has been found that the bad efficacy, slow onset, long course of treatment, side effects can be significantly avoided for existing clinical IBD drugs, it can reduce the patients pain during the treatment in this invention. The rehabilitation and quality of life of the patients have been largely improved. The drug will play an important role in the prevention and treatment of IBD in this invention, and has broad application prospects.


Patent
Shanghai Serum Biotechnology Co. and Academy Of Military Medical Science | Date: 2015-09-23

The present invention provides human anti-human epidermal growth factor receptor (EGFR) antibodies and their encoding genes and applications thereof. By gene engineering means and phage surface display technology, the present invention screens anti-human EGFR gene engineering single chain antibody from fully synthetic single chain human antibody library, and obtains the antibody variable gene sequence thereof, and based thereon, constructs intact human monoclonal antibody, to further obtain high-purity antibody protein. The binding affinity of the antibody of the present invention with human EGFR is no more than 1 nM, and the mutants affinity thereof is no more than 10 nM; and the identification of the immunity activity and bioactivity of antibodies protein IgG is completed, confirming that the antibody of the present invention has good bioactivity of inhibiting the tumor growth of EGFR expressing cell A431 tumor-bearing model mouse. The antibodies of the present invention provides specific antibody drugs for preventing and treating EGFR targeted tumor and other diseases such as inflammation and autoimmune diseases.


Patent
Academy Of Military Medical Science and Han | Date: 2016-02-10

The present invention discloses a protamine-like peptide and the pharmaceutical salt and use thereof. The protamine-like peptide is a linear polypeptide consisting of 9 to 20 basic amino acid residues, and the basic amino acid is one or more kinds selected from the group consisting of Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H). It has been proved that the series of protamine-like peptides and the pharmaceutical salts thereof function as the protamine to neutralize and antagonize heparin in the blood. Therefore, they can be used clinically in stead of the protamine to eliminate and neutralize the bleeding tendency caused by heparin in the blood.


He B.,Academy of Military Medical science
Emerging infectious diseases | Year: 2013

During an analysis of the virome of bats from Myanmar, a large number of reads were annotated to orthohepadnaviruses. We present the full genome sequence and a morphological analysis of an orthohepadnavirus circulating in bats. This virus is substantially different from currently known members of the genus Orthohepadnavirus and represents a new species.


Cui M.,Academy of Military Medical science
PloS one | Year: 2013

Brucella melitensis is a facultative intracellular bacterium that replicates within macrophages. The ability of brucellae to survive and multiply in the hostile environment of host macrophages is essential to its virulence. The RNA-binding protein Hfq is a global regulator that is involved in stress resistance and pathogenicity. Here we demonstrate that Hfq is essential for stress adaptation and intracellular survival in B. melitensis. A B. melitensis hfq deletion mutant exhibits reduced survival under environmental stresses and is attenuated in cultured macrophages and mice. Microarray-based transcriptome analyses revealed that 359 genes involved in numerous cellular processes were dysregulated in the hfq mutant. From these same samples the proteins were also prepared for proteomic analysis to directly identify Hfq-regulated proteins. Fifty-five proteins with significantly affected expression were identified in the hfq mutant. Our results demonstrate that Hfq regulates many genes and/or proteins involved in metabolism, virulence, and stress responses, including those potentially involved in the adaptation of Brucella to the oxidative, acid, heat stress, and antibacterial peptides encountered within the host. The dysregulation of such genes and/or proteins could contribute to the attenuated hfq mutant phenotype. These findings highlight the involvement of Hfq as a key regulator of Brucella gene expression and facilitate our understanding of the role of Hfq in environmental stress adaptation and intracellular survival of B. melitensis.


Patent
Academy Of Military Medical Science | Date: 2014-01-23

Disclosed in the present invention is new use of saturated amine compounds for use in preparing medicines to resist radiation damage and promoting regeneration and repair of radiation-damaged tissues.


Patent
Academy Of Military Medical Science | Date: 2013-02-06

A multiassay immunochromatographic chip comprises: a viscous bottom lining (1), a sample pad (2), a bonding pad (3), an analysis membrane (4) and a water absorption pad (5).The bonding pad (3) fixedly has a plurality of assay binding substances (6) and a control binding substance (7), the assay binding substance (6) is formed by joining a tracer (8) and a liquid-phase detection probe (9), the control binding substance (7) is formed by joining the tracer (8) and a liquid-phase control probe (11); the analysis membrane (4) is provided with a detection matrix unit (12), each detection matrix unit comprises a detection zone (13) and a control zone (14), wherein the detection zone (13) consists of a plurality of solid phase detection probes (15) and the control zone (14) consists of a solid phase control probe (16). Organic integration of immunochromatographic reaction modes and chip assay matrix settings enables high throughput assay of multiple target substances with one sample load.


Disclosed in the present invention is new use of saturated amine compounds for use in preparing medicines to resist radiation damage and promoting regeneration and repair of radiation-damaged tissues. Experiments show that the saturated amine compounds can increase the counts of white blood cells (WBC), red blood cells (RBC) and platelets (PLT) in the peripheral blood of radiation-damaged animals, promote multiplication of bone marrow hematopoietic stem/progenitor cells and restoration of the hematopoietic system, and bring favorable reparative effects to the intestinal, hepatic and pulmonary tissues of radiation-damaged mice, thus significantly improving the survival rate of radiation-damaged animals.


Patent
Academy Of Military Medical Science | Date: 2016-04-27

Disclosed in the invention are a substance having tyrosine kinase inhibitory activity and a preparation method and use thereof, wherein the substance is a compounds having the structure of general formula (I) or the geometrical isomer and medicinal salt thereof. The invention, through tyrosine kinase inhibitory activity evaluation and related experiments, confirms that these compounds have a good tyrosine kinase inhibitory activity, and can inhibit a variety of tumor cells, and it can be developed into drugs for preventing and treating tumorous diseases, especially resisting liver cancer, lung cancer and neuroblastoma.

Loading Academy of Military Medical Science collaborators
Loading Academy of Military Medical Science collaborators